Literature DB >> 14523098

Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition.

Francesco Fornai1, Paola Lenzi, Marco Gesi, Michela Ferrucci, Gloria Lazzeri, Carla L Busceti, Riccardo Ruffoli, Paola Soldani, Stefano Ruggieri, Maria G Alessandri, Antonio Paparelli.   

Abstract

Mutation of genes encoding for various components of a metabolic pathway named the ubiquitin-proteasome system (UP) leads to inherited forms of Parkinson's disease (PD), whereas various components of the UP are constantly present within neuronal inclusions, Lewy bodies, that characterize most genetic and sporadic forms of PD. It has been hypothesized that impairment of this metabolic pathway might be a common mechanism for the onset of PD, and a recent study demonstrated a dysfunction of the UP system within the substantia nigra of patients affected by sporadic PD. In search for the mechanisms underlying the selective toxicity for nigral neurons after inhibition of the UP system, we explored the selective effects after striatal microinfusions of lactacystin or epoxomycin and potential retrograde changes within the ipsilateral substantia nigra. We found that neurotoxicity was selective for striatal dopamine (DA) components and led to retrograde apoptosis within nigral DA cells, which developed neuronal inclusions staining for antigens of the UP system. We found the same ultrastructural features characterizing inclusions obtained in vivo and in vitro after UP inhibition. In vivo, lactacystin-epoxomycin-induced toxicity was suppressed by inhibiting DA synthesis. Similarly, in vitro inclusions and apoptosis were prevented by reducing endogenous DA. On the other hand, toxicity of proteasome inhibition was enhanced by drugs augmenting DA availability: l-3,4-dihydroxyphenylalanine, monoamine oxidase blockers, and DA beta-hydroxylase blockers. These findings demonstrate that impairment of the UP system produces cell death and neuronal inclusions selectively for DA-containing neurons that depend on the occurrence of endogenous DA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523098      PMCID: PMC6740387     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  46 in total

1.  Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions.

Authors:  Sreeganga Chandra; Francesco Fornai; Hyung-Bae Kwon; Umar Yazdani; Deniz Atasoy; Xinran Liu; Robert E Hammer; Giuseppe Battaglia; Dwight C German; Pablo E Castillo; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-01       Impact factor: 11.205

Review 2.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

3.  Alpha-synuclein transmission and mitochondrial toxicity in primary human foetal enteric neurons in vitro.

Authors:  Nady Braidy; Wei-Ping Gai; Ying Hua Xu; Perminder Sachdev; Gilles J Guillemin; Xing-Mai Jiang; J William O Ballard; Martin P Horan; Zhi Ming Fang; Beng H Chong; Daniel Kam Yin Chan
Journal:  Neurotox Res       Date:  2013-09-12       Impact factor: 3.911

4.  Control of chronic pain by the ubiquitin proteasome system in the spinal cord.

Authors:  Michael H Ossipov; Igor Bazov; Luis R Gardell; Justin Kowal; Tatiana Yakovleva; Ivan Usynin; Tomas J Ekström; Frank Porreca; Georgy Bakalkin
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

Review 5.  L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.

Authors:  Norio Ogawa; Masato Asanuma; Ikuko Miyazaki; Francisco J Diaz-Corrales; Ko Miyoshi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

6.  Proteasome inhibitor does not enhance MPTP neurotoxicity in mice.

Authors:  Naoto Kadoguchi; Masahiro Umeda; Hiroyuki Kato; Tsutomu Araki
Journal:  Cell Mol Neurobiol       Date:  2008-03-14       Impact factor: 5.046

7.  Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition.

Authors:  Chaoshi Niu; Jiaming Mei; Qi Pan; Xianming Fu
Journal:  Stereotact Funct Neurosurg       Date:  2009-02-18       Impact factor: 1.875

8.  Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems.

Authors:  Nicholas MacInnes; Mahmoud M Iravani; Elaine Perry; Margaret Piggott; Robert Perry; Peter Jenner; Clive Ballard
Journal:  J Neural Transm (Vienna)       Date:  2008-04-10       Impact factor: 3.575

9.  Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.

Authors:  Mari H Savolainen; Katrina Albert; Mikko Airavaara; Timo T Myöhänen
Journal:  Exp Brain Res       Date:  2017-04-24       Impact factor: 1.972

10.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.